

Masato Nakai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4722386/publications.pdf>

Version: 2024-02-01

46
papers

811
citations

430442

18
h-index

552369

26
g-index

47
all docs

47
docs citations

47
times ranked

1042
citing authors

#	ARTICLE	IF	CITATIONS
1	Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 232.	1.7	6
2	Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. <i>PLoS ONE</i> , 2022, 17, e0261760.	1.1	17
3	Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication. <i>Scientific Reports</i> , 2022, 12, 1449.	1.6	9
4	Overestimated Renal Function in Patients with Liver Cirrhosis Predicts Poor Prognosis. <i>Hepatology Research</i> , 2022, , .	1.8	4
5	Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients. <i>PLoS ONE</i> , 2022, 17, e0270786.	1.1	1
6	Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling. <i>Carcinogenesis</i> , 2021, 42, 58-69.	1.3	21
7	Tenofovir disoproxil fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. <i>Journal of Gastroenterology</i> , 2021, 56, 168-180.	2.3	29
8	Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma. <i>PLoS ONE</i> , 2021, 16, e0247728.	1.1	3
9	Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C. <i>Scientific Reports</i> , 2021, 11, 9207.	1.6	8
10	Treatment outcomes of stereotactic body radiation therapy using a real-time tumor tracking radiotherapy system for hepatocellular carcinomas. <i>Hepatology Research</i> , 2021, 51, 870-879.	1.8	8
11	Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia. <i>Nutrients</i> , 2021, 13, 2415.	1.7	8
12	Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. <i>Hepatology Research</i> , 2021, 51, 979-989.	1.8	20
13	Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI. <i>Cancers</i> , 2021, 13, 3633.	1.7	10
14	Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting. <i>JGH Open</i> , 2020, 4, 54-60.	0.7	36
15	Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin. <i>Supportive Care in Cancer</i> , 2020, 28, 3251-3257.	1.0	5
16	Computed tomography, not bioelectrical impedance analysis, is the proper method for evaluating changes in skeletal muscle mass in liver disease. <i>JCSM Rapid Communications</i> , 2020, 3, 103-114.	0.6	8
17	Durable response without recurrence to Tolvaptan improves long-term survival. <i>Journal of Gastroenterology</i> , 2020, 55, 1150-1161.	2.3	4
18	Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria. <i>Hepatology Research</i> , 2020, 50, 966-977.	1.8	35

#	ARTICLE	IF	CITATIONS
19	Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1782-1788.	1.4	22
20	High serum angiotensin-converting enzyme 2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C. <i>Hepatology Research</i> , 2020, 50, 671-681.	1.8	20
21	Baseline angiotensin-converting enzyme 2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma. <i>JGH Open</i> , 2020, 4, 880-888.	0.7	13
22	Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection. <i>Journal of Gastroenterology</i> , 2019, 54, 78-86.	2.3	19
23	Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysis. <i>Hepatology Research</i> , 2019, 49, 1294-1304.	1.8	32
24	Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to anti-hepatitis C virus drugs. <i>Hepatology Research</i> , 2019, 49, 1275-1285.	1.8	8
25	Quantifying Protein-Specific N-Glycome Profiles by Focused Protein and Immunoprecipitation Glycomics. <i>Journal of Proteome Research</i> , 2019, 18, 3133-3141.	1.8	12
26	The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment. <i>Internal Medicine</i> , 2019, 58, 943-947.	0.3	5
27	Comparative Glycomic Analysis of Sialyl Linkage Isomers by Sialic Acid Linkage-Specific Alkylamidation in Combination with Stable Isotope Labeling of 1,2,3-Linked Sialic Acid Residues. <i>Analytical Chemistry</i> , 2019, 91, 13343-13348.	3.2	12
28	Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection. <i>Journal of Gastroenterology</i> , 2019, 54, 641-649.	2.3	21
29	Evaluation of clinical utility of PIVKA-II using a chemiluminescent immunoassay. <i>Acta Hepatologica Japonica</i> , 2019, 60, 397-404.	0.0	0
30	Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases. <i>Internal Medicine</i> , 2019, 58, 797-802.	0.3	4
31	Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction. <i>Hepatology Research</i> , 2018, 48, 529-538.	1.8	15
32	Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan. <i>Journal of Gastroenterology</i> , 2018, 53, 119-128.	2.3	49
33	Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study. <i>Hepatology Research</i> , 2018, 48, E146-E154.	1.8	1
34	Increased serum C-reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis. <i>Hepatology Research</i> , 2018, 48, E311-E319.	1.8	11
35	Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection. <i>Journal of Hepatology</i> , 2017, 67, 1106-1108.	1.8	21
36	A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma. <i>Drugs in R and D</i> , 2017, 17, 381-388.	1.1	12

#	ARTICLE	IF	CITATIONS
37	Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. <i>Journal of Gastroenterology</i> , 2017, 52, 1122-1129.	2.3	32
38	Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment. <i>Hepatology Research</i> , 2017, 47, 1127-1136.	1.8	31
39	Hepatitis B virus X protein impairs interferon signaling via upregulation of suppressor of cytokine signaling 3 and protein phosphatase 2A. <i>Journal of Medical Virology</i> , 2017, 89, 267-275.	2.5	29
40	Anti-adipogenic and antiviral effects of L-carnitine on hepatitis C virus infection. <i>Journal of Medical Virology</i> , 2017, 89, 857-866.	2.5	20
41	Combination of neutrophil-lymphocyte ratio and early desferrioxamine carboxyprothrombin change ratio as a useful predictor of treatment response for hepatic arterial infusion chemotherapy against advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2017, 47, 533-541.	1.8	13
42	Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection. <i>Hepatology Research</i> , 2016, 46, 1294-1303.	1.8	27
43	Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2016, 51, 733-740.	2.3	103
44	Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 4, 320-327.	0.7	18
45	Interferon (IFN) and Cellular Immune Response Evoked in RNA-Pattern Sensing During Infection with Hepatitis C Virus (HCV). <i>Sensors</i> , 2015, 15, 27160-27173.	2.1	14
46	Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions. <i>Hepatology Research</i> , 2015, 45, 837-845.	1.8	15